Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care.

Chino F, Peppercorn JM, Rushing C, Kamal AH, Altomare I, Samsa G, Zafar SY.

JAMA Oncol. 2017 Aug 10. doi: 10.1001/jamaoncol.2017.2148. [Epub ahead of print] No abstract available.

PMID:
28796862
2.

A randomized pilot trial of a videoconference couples communication intervention for advanced GI cancer.

Porter LS, Keefe FJ, Baucom DH, Olsen M, Zafar SY, Uronis H.

Psychooncology. 2017 Jul;26(7):1027-1035. doi: 10.1002/pon.4121. Epub 2016 Mar 8.

PMID:
28691761
3.

How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.

Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB.

Am Soc Clin Oncol Educ Book. 2017;37:35-39. doi: 10.14694/EDBK_174893.

4.

Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?

Zafar SY, Peppercorn JM.

J Clin Oncol. 2017 Jul 1;35(19):2113-2116. doi: 10.1200/JCO.2016.71.7280. Epub 2017 May 1. No abstract available.

PMID:
28459612
5.

The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.

Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY.

J Manag Care Spec Pharm. 2017 Apr;23(4):407-411. doi: 10.18553/jmcp.2017.23.4.407.

6.

Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.

Zafar SY, Peppercorn J, Asabere A, Bastian A.

J Oncol Pract. 2017 Mar;13(3):e240-e248. doi: 10.1200/JOP.2016.017509. Epub 2017 Jan 31.

PMID:
28140745
7.

Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.

Mowery YM, Salama JK, Zafar SY, Moore HG, Willett CG, Czito BG, Hopkins MB, Palta M.

Cancer. 2017 Apr 15;123(8):1434-1441. doi: 10.1002/cncr.30461. Epub 2016 Dec 16.

PMID:
27984651
8.

A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?

Wollins DS, Zafar SY.

Oncologist. 2016 Oct;21(10):1157-1160. Epub 2016 Aug 22. No abstract available.

9.

Validation and Quality Assessment of the Kilimanjaro Cancer Registry.

Zullig LL, Schroeder K, Nyindo P, Namwai T, Silayo E, Msomba A, Munishi MO, Karia F, Muiruri C, Bartlett J, Maro V, Zafar SY.

J Glob Oncol. 2016 Apr 27;2(6):381-386. doi: 10.1200/JGO.2015.002873. eCollection 2016 Dec.

10.

Comparing Unmet Needs to Optimize Quality: Characterizing Inpatient and Outpatient Palliative Care Populations.

Hochman MJ, Wolf S, Zafar SY, Portman D, Bull J, Kamal AH.

J Pain Symptom Manage. 2016 Jun;51(6):1033-1039.e3. doi: 10.1016/j.jpainsymman.2015.12.338. Epub 2016 Apr 2.

PMID:
27046299
11.

Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer.

Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, Schrag D.

J Clin Oncol. 2016 May 20;34(15):1732-40. doi: 10.1200/JCO.2015.63.2232. Epub 2016 Feb 29.

12.

Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care.

Altomare I, Irwin B, Zafar SY, Houck K, Maloney B, Greenup R, Peppercorn J.

J Oncol Pract. 2016 Mar;12(3):e281-8, 247-8. doi: 10.1200/JOP.2015.007401. Epub 2016 Feb 16.

13.

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, de Souza J, Wong YN.

Value Health. 2016 Jan;19(1):88-98. doi: 10.1016/j.jval.2015.10.005. Epub 2015 Nov 26.

14.

Financial Toxicity of Cancer Care: It's Time to Intervene.

Zafar SY.

J Natl Cancer Inst. 2015 Dec 11;108(5). pii: djv370. doi: 10.1093/jnci/djv370. Print 2016 May.

PMID:
26657334
15.

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators.

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.

16.

The utility of cost discussions between patients with cancer and oncologists.

Zafar SY, Chino F, Ubel PA, Rushing C, Samsa G, Altomare I, Nicolla J, Schrag D, Tulsky JA, Abernethy AP, Peppercorn JM.

Am J Manag Care. 2015 Sep;21(9):607-15.

17.

Adjuvant Chemotherapy for Stage II Rectal Cancer.

Deming D, Uboha N, Zafar SY, Rosenberg S, Bassetti M, Glasgow S, Borden EC, Lubner S.

Semin Oncol. 2015 Dec;42(6):e99-107. doi: 10.1053/j.seminoncol.2015.09.033. Epub 2015 Sep 21. Review. No abstract available.

PMID:
26615141
18.

Is obesity an advantage in patients with colorectal cancer?

Kasi PM, Zafar SY, Grothey A.

Expert Rev Gastroenterol Hepatol. 2015;9(11):1339-42. doi: 10.1586/17474124.2015.1089170. Epub 2015 Sep 14. Review.

PMID:
26366838
19.

Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress.

Nipp RD, Zullig LL, Samsa G, Peppercorn JM, Schrag D, Taylor DH Jr, Abernethy AP, Zafar SY.

Psychooncology. 2016 Jun;25(6):719-25. doi: 10.1002/pon.3911. Epub 2015 Jul 7.

PMID:
26149817
20.

Best supportive care in clinical trials: review of the inconsistency in control arm design.

Nipp RD, Currow DC, Cherny NI, Strasser F, Abernethy AP, Zafar SY.

Br J Cancer. 2015 Jun 30;113(1):6-11. doi: 10.1038/bjc.2015.192. Epub 2015 Jun 11. Review.

Supplemental Content

Loading ...
Support Center